



Oncology-focused Biotech Selects Cardiocore as Preferred Provider

Leading Core Lab to Provide ECG, ECHO and Scientific Consulting Services

Washington, DC—Cardiocore, a premier centralized cardiac testing lab, announced today that it has been selected as a preferred provider by a growing West Coast biotechnology organization with a robust oncology treatment pipeline. During their selection process, this drug developer reviewed the scientific expertise, global logistics capabilities and data management systems of the major cardiac core lab vendors.

Key considerations included Cardiocore's deep experience in the design and conduct of oncology clinical trials, and its broad range of cardiac safety services including electrocardiography (ECG), echocardiography (ECHO) and multigated acquisition scanning (MUGA). To serve this sponsor's data management needs, Cardiocore will customize all data outputs per the sponsor's unique specifications, and will deliver data through the CardioPortal™ system. Cardiocore's advanced web service presents comprehensive cardiac safety reports to the sponsor and investigative sites, in real time.

As part of the preferred provider relationship, Cardiocore's scientific and operational leaders have begun a series of cardiac safety training seminars for the client's translational medicine and clinical teams. These sessions provide strategic planning, operational and clinical development support across all therapeutic groups in the sponsor organization.

Cardiocore Chief Executive Officer, Jennifer Cotteleer said, "We are proud to earn this preferred provider award from another leading biotechnology organization." She added, "We appreciate this client's interest in expertise and innovation, and we look forward to many years of providing them the best quality scientific consulting, global cardiac testing services and customized data management."

***About Cardiocore:** Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company's advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore's U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com*